SRTA — Strata Critical Medical, Inc.

Summary of Strata Critical Medical Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Increased 87.4% year-over-year to $67.4 million, up from $35.9 million in Q1 2025.
• Logistics Revenue: Grew 32.4% to $47.6 million, but fell 3.3% sequentially from Q4 2025 due to customer mix and winter weather impacts.
• Clinical Revenue: Generated $19.8 million, a 12.7% sequential increase, driven by NRP and Surgical Recovery services.
• Gross Profit: Doubled to $14.1 million, with gross margin improving to 21% from 19.6% a year prior.
• Adjusted EBITDA: Decreased to $6.4 million from $7 million in Q4 2025, with a margin of 9.5%.
• Operating Cash Flow: Reported at $3.9 million, with free cash flow before aircraft acquisitions at $2.1 million.
• Cash Position: Ended the quarter with $58.8 million in cash and short-term investments.

2. Strategic Updates and Business Highlights

• M&A Activity: Acquired Ohio Valley Perfusion Associates for $1 million, expected to add $100,000 in adjusted EBITDA this year. The company is pursuing additional M&A opportunities across various segments.
• Operational Expansion: Opened new aviation bases, including a combined Logistics and Clinical base in Chicago, enhancing service capabilities and efficiency.
• Market Positioning: Strata is positioned as a leader in third-party surgical recovery and NRP, with increasing adoption in the transplant community.
• Clinical Growth: Strong performance in the Clinical division, with new customer acquisitions and cross-selling opportunities.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated at $260 million to $275 million, with adjusted EBITDA of $29 million to $33 million.
• Q2 Expectations: Anticipate low single-digit revenue growth sequentially and an improvement in adjusted EBITDA margin to approximately 10%.
• Logistics Gross Margins: Expected to remain in the 20% range, influenced by fuel surcharges and customer mix.

4. Bad News, Challenges, or Points of Concern

• Logistics Revenue Decline: Experienced a sequential decline in logistics revenue due to a shift in customer mix towards lower-margin OPOs and adverse weather conditions affecting operations.
• Adjusted EBITDA Margin Pressure: The margin decreased sequentially, attributed to reduced gross margins and increased SG&A expenses.
• Deceased Donor Volumes: Although there was a sequential improvement in deceased donor activity, year-over-year numbers remain down, posing risks to future transplant volumes.

5. Notable Q&A Insights

• Customer Acquisition: Continued success in onboarding Clinical customers from Logistics, although the initial surge post-Keystone acquisition is stabilizing.
• Market Expansion: The Chicago hub is expected to enhance growth by providing local resources for organ recovery, although new customers are not yet operational.
• Impact of Oil Prices: Fuel costs are passed through to customers, mitigating potential negative impacts on profitability.
• Acquisition Structures: Flexible deal structures are being offered to potential acquisition targets, often including equity components to align incentives.
• Regulatory Scrutiny: Increased scrutiny on donor surgeon qualifications is seen as a positive evolution, with Strata preparing to meet future certification requirements.

Overall, Strata Critical Medical reported strong growth in Q1 2026, driven by its logistics and clinical divisions, while navigating challenges related to customer mix and external market conditions. The company remains optimistic about future growth through strategic acquisitions and operational efficiencies.